286 related articles for article (PubMed ID: 24530487)
1. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
[TBL] [Abstract][Full Text] [Related]
2. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
Chen Z; Tighiouart M; Kowalski J
Contemp Clin Trials; 2012 Sep; 33(5):949-58. PubMed ID: 22561391
[TBL] [Abstract][Full Text] [Related]
3. Bayesian dose escalation with overdose and underdose control utilizing all toxicities in Phase I/II clinical trials.
Tu J; Chen Z
Biom J; 2024 Jan; 66(1):e2200189. PubMed ID: 38047521
[TBL] [Abstract][Full Text] [Related]
4. Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information.
Zhang Y; Kutner M; Chen Z
Biom J; 2021 Oct; 63(7):1476-1492. PubMed ID: 33969525
[TBL] [Abstract][Full Text] [Related]
5. Dose-finding approach for dose escalation with overdose control considering incomplete observations.
Mauguen A; Le Deley MC; Zohar S
Stat Med; 2011 Jun; 30(13):1584-94. PubMed ID: 21351289
[TBL] [Abstract][Full Text] [Related]
6. GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials.
Dinart D; Fraisse J; Tosi D; Mauguen A; Touraine C; Gourgou S; Le Deley MC; Bellera C; Mollevi C
BMC Med Inform Decis Mak; 2020 Jun; 20(1):134. PubMed ID: 32580715
[TBL] [Abstract][Full Text] [Related]
7. Rolling continual reassessment method with overdose control: An efficient and safe dose escalation design.
Zhu J; Sabanés Bové D; Liao Z; Beyer U; Yung G; Sarkar S
Contemp Clin Trials; 2021 Aug; 107():106436. PubMed ID: 34000410
[TBL] [Abstract][Full Text] [Related]
8. Escalation with overdose control using time to toxicity for cancer phase I clinical trials.
Tighiouart M; Liu Y; Rogatko A
PLoS One; 2014; 9(3):e93070. PubMed ID: 24663812
[TBL] [Abstract][Full Text] [Related]
9. A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
Tighiouart M; Cook-Wiens G; Rogatko A
J Biopharm Stat; 2018; 28(3):562-574. PubMed ID: 28858566
[TBL] [Abstract][Full Text] [Related]
10. Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials.
Wheeler GM; Sweeting MJ; Mander AP
Stat Med; 2017 Jul; 36(16):2499-2513. PubMed ID: 28295513
[TBL] [Abstract][Full Text] [Related]
11. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
Tighiouart M; Rogatko A; Babb JS
Stat Med; 2005 Jul; 24(14):2183-96. PubMed ID: 15909291
[TBL] [Abstract][Full Text] [Related]
12. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.
Yuan Y; Lin R; Li D; Nie L; Warren KE
Clin Cancer Res; 2018 Oct; 24(20):4921-4930. PubMed ID: 29769209
[TBL] [Abstract][Full Text] [Related]
13. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
Du Y; Yin J; Sargent DJ; Mandrekar SJ
J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
[TBL] [Abstract][Full Text] [Related]
14. A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.
Tighiouart M; Li Q; Rogatko A
Stat Med; 2017 Jan; 36(2):280-290. PubMed ID: 27060889
[TBL] [Abstract][Full Text] [Related]
15. A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method.
North B; Kocher HM; Sasieni P
BMC Cancer; 2019 Jun; 19(1):632. PubMed ID: 31242873
[TBL] [Abstract][Full Text] [Related]
16. Escalation with overdose control for phase I drug-combination trials.
Shi Y; Yin G
Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
[TBL] [Abstract][Full Text] [Related]
17. Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials.
Chen Z; Yuan Y; Li Z; Kutner M; Owonikoko T; Curran WJ; Khuri F; Kowalski J
Contemp Clin Trials; 2015 Jul; 43():133-41. PubMed ID: 26012358
[TBL] [Abstract][Full Text] [Related]
18. A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in Phase I clinical trials.
Chen Z; Krailo MD; Azen SP; Tighiouart M
Contemp Clin Trials; 2010 Sep; 31(5):473-82. PubMed ID: 20609419
[TBL] [Abstract][Full Text] [Related]
19. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
Normolle D; Lawrence T
J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
[TBL] [Abstract][Full Text] [Related]
20. Adaptive Estimation of Personalized Maximum Tolerated Dose in Cancer Phase I Clinical Trials Based on All Toxicities and Individual Genomic Profile.
Chen Z; Li Z; Zhuang R; Yuan Y; Kutner M; Owonikoko T; Curran WJ; Kowalski J
PLoS One; 2017; 12(1):e0170187. PubMed ID: 28125617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
